+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Usher Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 133 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5970265
The 7 major Usher syndrome markets reached a value of US$ 1.2 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 1.7 Billion by 2034, exhibiting a growth rate (CAGR) of 3.95% during 2023-2034.

The Usher syndrome market has been comprehensively analyzed in this report titled "Usher Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Usher syndrome refers to a rare genetic disorder characterized by a combination of hearing loss or deafness and progressive vision loss. This condition primarily affects the inner ear, leading to varying degrees of hearing impairment, and also involves the gradual deterioration of vision due to retinitis pigmentosa, a degenerative eye disorder. The symptoms of the ailment can differ widely among patients and can occur during infancy or adulthood. Hearing loss or deafness is often present from birth or early childhood, and it can range from mild to profound. The vision loss associated with retinitis pigmentosa typically emerges later in childhood or adolescence, causing night blindness and a narrowing field of vision, ultimately leading to tunnel vision or complete blindness over time. The diagnosis of Usher syndrome involves comprehensive medical and genetic assessments. Audiological tests can determine the extent of hearing loss, while visual field tests and retinal imaging can help to identify retinitis pigmentosa.

The escalating prevalence of mutations in genes, such as MYO7A, USH1C, and CDH23, which are integral to the proper functioning of the auditory and visual systems, is primarily driving the Usher syndrome market. In addition to this, the inflating utilization of efficient therapeutic solutions, including cochlear implants for hearing loss and retinal implants for visual impairments, is also creating a positive outlook for the market. Moreover, the widespread adoption of audiological and ophthalmological rehabilitation techniques, since they help to improve the independence and quality of life for individuals suffering from the illness, is further bolstering the market growth. Apart from this, the growing research and development activities that are poised to uncover novel treatment modalities and medications, which can alleviate or even reverse the symptoms of Usher syndrome are acting as another significant growth-inducing factor. Additionally, the emerging popularity of antioxidant supplements, such as vitamin A and vitamin E, to slow down disease progression is also augmenting the market growth. Furthermore, the escalating application of gene therapy, since it involves delivering corrective genetic material to cells, thereby rectifying or replacing the faulty genes responsible for the disorder, is expected to drive the Usher syndrome market during the forecast period.

This report provides an exhaustive analysis of the Usher syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Usher syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Usher syndrome market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the Usher syndrome market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the Usher syndrome market

Competitive Landscape:

This report also provides a detailed analysis of the current usher syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the Usher syndrome market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the Usher syndrome market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the Usher syndrome market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of Usher syndrome across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Usher syndrome by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of Usher syndrome by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with Usher syndrome across the seven major markets?
  • What is the size of the Usher syndrome patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of Usher syndrome?
  • What will be the growth rate of patients across the seven major markets?

Usher Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for Usher syndrome drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Usher syndrome market?
  • What are the key regulatory events related to the Usher syndrome market?
  • What is the structure of clinical trial landscape by status related to the Usher syndrome market?
  • What is the structure of clinical trial landscape by phase related to the Usher syndrome market?
  • What is the structure of clinical trial landscape by route of administration related to the Usher syndrome market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Usher Syndrome - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Usher Syndrome - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Usher Syndrome - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 Usher Syndrome - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Usher Syndrome - Unmet Needs10 Usher Syndrome - Key Endpoints of Treatment
11 Usher Syndrome - Marketed Products
11.1 List of Usher Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Usher Syndrome - Pipeline Drugs
12.1 List of Usher Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 NT 501 - Neurotech Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ultevursen - ProQR Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Usher Syndrome - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Usher Syndrome - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Usher Syndrome - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Usher Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Usher Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Usher Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Usher Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Usher Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Usher Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Usher Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Usher Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Usher Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Usher Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Usher Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Usher Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Usher Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Usher Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Usher Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Usher Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Usher Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Usher Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Usher Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Usher Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Usher Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Usher Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Usher Syndrome - Access and Reimbursement Overview
16 Usher Syndrome - Recent Events and Inputs From Key Opinion Leaders
17 Usher Syndrome Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Usher Syndrome Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information